Abstract
In the first two years of the COVID-19 pandemic, influenza transmission decreased substantially worldwide meaning that health systems were not faced with simultaneous respiratory epidemics. In 2022, however, substantial influenza transmission returned to Nicaragua where it co-circulated with SARS-CoV-2 causing substantial disease burden.
Competing Interest Statement
Dr Gordon reports serving on a respiratory syncytial virus vaccine scientific advisory board for Janssen Pharmaceuticals and a COVID-19 scientific advisory board for Gilead Sciences outside the submitted work. No other disclosures are reported.
Funding Statement
This work was supported by the National Institute for Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health (grants R01 AI120997 and U01 AI144616 and contract HHSN272201400006C).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Michigan Institutional Review Board gave ethical approval for this work. The Nicaragua Ministry of Health Institutional Review Board also gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Individual-level data may be shared with outside investigators following University of Michigan IRB approval. Please contact Aubree Gordon (gordonal{at}umich.edu) to arrange for data access.
